Zinc and ferritin in haemoglobinopathies an observational study

AUTHOR(s) : Teli AB, Sarma Nibedita, Baruah Aditi
DOI No. : 10.31741/ijhrmlp.v5.i2.2019.14

ABSTRACT :
Introduction: It has been estimated that with a population of 1000 million at the millennium year 2000 and a birth rate of 25 per thousand, there would be about 45 million carriers and about 15,000 infants born each year with haemoglobinopathies in India. The present study is taken up with special emphasis to paediatric patients with thalassemia major and sickle cell anaemia. Objective: To measure serum zinc and ferritin levels in paediatric thalassemia major and sickle cell anemia patients. Materials and methods: Serum zinc estimated by colorimetric method and ferritin by immunoradiometric method. Result: Mean ± S.D. of zinc in thalassemia major found to be lower than sickle cell disease with zinc being in lower side of normal range in sickle cell anemia cases suggesting hypozincemia in both groups whereas Mean ± S.D. of ferritin found to be higher in both the groups indicating iron overload in both the groups. Conclusion: Decreased zinc level and increased ferritin level found in the study may be caused by disease itself or may be consequence of repeated transfusion which has to be ruled out by further study in larger patient groups and meanwhile nutritional supplement of zinc and iron chelation therapy must be mandatory in these group of patients.

PDF
Registered Office Address:
House No: One, Karmabir Bordoloi Path, Wireless,
Rukmini Nagar, Dispur-06, Assam, India

Mobile: 09435017802
Email: editor@ijhrmlp.org
Website: www.ijhrmlp.org
IJHRMLP is an open-access journal, and the articles published are instantly available to read and use again. The published articles thus can be downloaded, shared, and reused without restriction if the contributing original authors are appropriately cited. Author(s) retain the copyright of their article, with articles licensed to AHRME and the journal following the Creative Commons Attribution License (CC-BY).
Maintain By Prism Infosys